The Retatrutide Phase 2 Dose Study: Reading the Trial Arms
Understand the distinction between randomized research groups and an approved dosing schedule, including the different starting strategies in the phase 2 obesity trial.
FormBlends Editorial Research · Updated 2026-09-27
The correct trial record
Jastreboff and colleagues reported the phase 2 obesity trial in the New England Journal of Medicine in 2023. Its registration is NCT04881760. NCT05298254 is an unrelated herpes simplex virus immunotherapy study and is not a source for retatrutide dosing.
What the randomized groups compared
The study included a 1 mg group; 4 mg target groups starting at 2 mg or 4 mg; 8 mg target groups starting at 2 mg or 4 mg; and a 12 mg target group starting at 2 mg, as well as placebo. These figures identify experimental groups. They are not preparation, escalation or injection instructions.
Why the distinction matters
A starting dose and a target dose are different study variables. The presence of both 2 mg and 4 mg starting strategies means that a universal 2 mg start is an inaccurate description. A 1 mg group also cannot be omitted from a complete account of the design. The publication reports outcomes and adverse events in the context of those groups.
No clinical schedule can be inferred
The study does not authorize compounding pharmacies to supply retatrutide or clinicians to improvise variants from an article. FDA states that it cannot be used in compounding under federal law. There is no approved retail dosing schedule. FormBlends does not prescribe, compound or sell retatrutide.